Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 79.3 Billion KRW | 157.66% |
| 2022 | 30.77 Billion KRW | -19.06% |
| 2021 | 38.02 Billion KRW | -66.3% |
| 2020 | 112.81 Billion KRW | -34.02% |
| 2019 | 170.98 Billion KRW | -1.43% |
| 2018 | 173.47 Billion KRW | -1.16% |
| 2017 | 175.5 Billion KRW | -12.09% |
| 2016 | 199.63 Billion KRW | -7.52% |
| 2015 | 215.86 Billion KRW | -0.88% |
| 2014 | 217.78 Billion KRW | 4.92% |
| 2013 | 207.56 Billion KRW | 8.7% |
| 2012 | 190.95 Billion KRW | -3.87% |
| 2011 | 198.63 Billion KRW | 16.48% |
| 2010 | 170.53 Billion KRW | 3.46% |
| 2009 | 164.83 Billion KRW | 17.18% |
| 2008 | 140.67 Billion KRW | 36.11% |
| 2007 | 103.35 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 77.23 Billion KRW | -2.6% |
| 2024 Q2 | 72.15 Billion KRW | -6.59% |
| 2023 Q1 | 62.77 Billion KRW | 103.95% |
| 2023 Q3 | 76.02 Billion KRW | 23.04% |
| 2023 FY | 79.3 Billion KRW | 157.66% |
| 2023 Q2 | 61.78 Billion KRW | -1.57% |
| 2023 Q4 | 79.3 Billion KRW | 4.32% |
| 2022 Q2 | 43.14 Billion KRW | 9.72% |
| 2022 Q4 | 30.77 Billion KRW | -25.25% |
| 2022 FY | 30.77 Billion KRW | -19.06% |
| 2022 Q1 | 39.32 Billion KRW | 3.41% |
| 2022 Q3 | 41.17 Billion KRW | -4.56% |
| 2021 Q4 | 38.02 Billion KRW | -22.77% |
| 2021 Q1 | 99.21 Billion KRW | -12.06% |
| 2021 Q2 | 59.77 Billion KRW | -39.75% |
| 2021 FY | 38.02 Billion KRW | -66.3% |
| 2021 Q3 | 49.23 Billion KRW | -17.64% |
| 2020 Q3 | 219.48 Billion KRW | 24.18% |
| 2020 Q2 | 176.74 Billion KRW | -1.25% |
| 2020 Q1 | 178.97 Billion KRW | 4.67% |
| 2020 FY | 112.81 Billion KRW | -34.02% |
| 2020 Q4 | 112.81 Billion KRW | -48.6% |
| 2019 Q1 | 179.39 Billion KRW | 3.42% |
| 2019 FY | 170.98 Billion KRW | -1.43% |
| 2019 Q4 | 170.98 Billion KRW | -2.05% |
| 2019 Q3 | 174.56 Billion KRW | -2.31% |
| 2019 Q2 | 178.68 Billion KRW | -0.4% |
| 2018 Q2 | 179.07 Billion KRW | 3.51% |
| 2018 Q4 | 173.47 Billion KRW | -2.03% |
| 2018 Q3 | 177.06 Billion KRW | -1.12% |
| 2018 FY | 173.47 Billion KRW | -1.16% |
| 2018 Q1 | 173 Billion KRW | -1.42% |
| 2017 Q3 | 175.94 Billion KRW | -2.27% |
| 2017 Q1 | 186.47 Billion KRW | -6.6% |
| 2017 FY | 175.5 Billion KRW | -12.09% |
| 2017 Q4 | 175.5 Billion KRW | -0.25% |
| 2017 Q2 | 180.03 Billion KRW | -3.45% |
| 2016 FY | 199.63 Billion KRW | -7.52% |
| 2016 Q3 | 189.35 Billion KRW | -2.88% |
| 2016 Q4 | 199.63 Billion KRW | 5.43% |
| 2016 Q2 | 194.97 Billion KRW | -7.1% |
| 2016 Q1 | 209.88 Billion KRW | -2.77% |
| 2015 Q3 | 212.65 Billion KRW | -2.41% |
| 2015 Q1 | 216.69 Billion KRW | -0.5% |
| 2015 FY | 215.86 Billion KRW | -0.88% |
| 2015 Q4 | 215.86 Billion KRW | 1.51% |
| 2015 Q2 | 217.89 Billion KRW | 0.56% |
| 2014 FY | 217.78 Billion KRW | 4.92% |
| 2014 Q3 | 214.35 Billion KRW | -0.97% |
| 2014 Q4 | 217.78 Billion KRW | 1.6% |
| 2014 Q2 | 216.44 Billion KRW | 0.43% |
| 2014 Q1 | 215.52 Billion KRW | 3.83% |
| 2013 Q1 | 197.98 Billion KRW | 3.68% |
| 2013 Q4 | 207.56 Billion KRW | -3.95% |
| 2013 FY | 207.56 Billion KRW | 8.7% |
| 2013 Q2 | 212.93 Billion KRW | 7.55% |
| 2013 Q3 | 216.11 Billion KRW | 1.49% |
| 2012 Q1 | 196.45 Billion KRW | 0.0% |
| 2012 Q4 | 190.95 Billion KRW | 0.0% |
| 2012 FY | 190.95 Billion KRW | -3.87% |
| 2011 Q2 | 207.9 Billion KRW | -1.04% |
| 2011 FY | 198.63 Billion KRW | 16.48% |
| 2011 Q3 | 203.56 Billion KRW | -2.09% |
| 2011 Q1 | 210.09 Billion KRW | 0.0% |
| 2010 Q2 | 170.65 Billion KRW | 2.38% |
| 2010 FY | 170.53 Billion KRW | 3.46% |
| 2010 Q3 | 163.97 Billion KRW | -3.91% |
| 2010 Q1 | 166.69 Billion KRW | 0.0% |
| 2009 Q2 | 153.15 Billion KRW | 2.55% |
| 2009 FY | 164.83 Billion KRW | 17.18% |
| 2009 Q3 | 156.06 Billion KRW | 1.9% |
| 2009 Q1 | 149.34 Billion KRW | 0.0% |
| 2008 FY | 140.67 Billion KRW | 36.11% |
| 2008 Q2 | 119.5 Billion KRW | 8.43% |
| 2008 Q1 | 110.21 Billion KRW | 0.0% |
| 2008 Q3 | 128.97 Billion KRW | 7.92% |
| 2007 Q2 | 97.86 Billion KRW | 6.76% |
| 2007 Q3 | 100.34 Billion KRW | 2.53% |
| 2007 FY | 103.35 Billion KRW | 0.0% |
| 2007 Q1 | 91.66 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1.854% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 91.471% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 88.785% |
| HANDOK Inc. | 449.7 Billion KRW | 82.366% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 7.434% |
| Yuhan Corporation | 712.33 Billion KRW | 88.867% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 87.451% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -398.925% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 90.69% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -48.148% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 61.481% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -5.495% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 46.343% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -12.642% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1.854% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -117.645% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 68.425% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 64.069% |
| JW Holdings Corporation | 827.51 Billion KRW | 90.417% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 81.853% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 86.486% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 79.109% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -13.34% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 67.346% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 75.991% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1.854% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 83.817% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 90.758% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 79.109% |
| Yuhan Corporation | 712.33 Billion KRW | 88.867% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 83.403% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 42.102% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 84.651% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 79.109% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 48.684% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 11.853% |
| CKD Bio Corp. | 170.76 Billion KRW | 53.56% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 67.464% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 49.7% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -84.34% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 87.463% |
| Boryung Corporation | 373.1 Billion KRW | 78.746% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 61.91% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 61.481% |
| JW Lifescience Corporation | 96.44 Billion KRW | 17.774% |